About Us Resources Catalysts Start Free Trial →

Loading…

Day Trader Sniper provides algorithmic alerts and analysis, not trade advice.
Not financial advice. Trade at your own risk.

Quick Links

Download The App Resources Market Feed Stocks

Catalysts About Us Support Privacy policy Terms of use

©2026 Day Trader Sniper - all rights reserved

Home›Catalysts›Regulatory and Clinical

Catalyst Category

Regulatory and Clinical

Live feed of every catalyst classified under Regulatory and Clinical.

CATALYSTS IN FEED

168

AVG MAX MOVE

+116.8%

POSITIVE MOVES

100%

LARGEST MOVE

+664.1%

DSMB Efficacy Met FDA 510(k) Cleared FDA Approval FDA Fast Track FDA Meeting FDA Meeting Granted Generic Drug Approved Inconclusive Topline Results IND Cleared for Study IND Filed NDA Resubmission Orphan Drug Designation Positive Subgroup Data Positive Topline Results Primary Endpoint Met SPA Agreement Study Complete Trial Enrollment Complete

Range–

Showing 7 of 168

Regulatory and ClinicalJan 13, 2026 · 5:30pm ET

FAMIFarmmi, Inc. Class A Ordinary Shares

Farmmi Achieved FDA Registration for Chino Warehouse

Regulatory milestone for the company's operations.

Be first on the next Regulatory and Clinical catalyst.

Day Trader Sniper alerts you the instant a setup like this triggers.

Download Free →

Max move

+44.8%

RVOL

4.1x

Max high

$1.81

Fuel

1h 8m

Regulatory and ClinicalJan 13, 2026 · 5:30pm ET

FAMIFarmmi, Inc. Class A Ordinary Shares+44.8%

Farmmi Achieved FDA Registration for Chino Warehouse

RVOL

4.1x

Max high

$1.81

Fuel

1h 8m

Regulatory and ClinicalJan 12, 2026 · 4:10am ET

JAGXJaguar Health, Inc.

Jaguar Health Awarded $240,000 FDA Grant for Canalevia-CA1

Grant supports treatment of chemotherapy-induced diarrhea in dogs.

Regulatory and ClinicalJan 12, 2026 · 4:10am ET

JAGXJaguar Health, Inc.+31.3%

Jaguar Health Awarded $240,000 FDA Grant for Canalevia-CA1

Regulatory and ClinicalJan 7, 2026 · 6:58pm ET

GRIGRI Bio, Inc. Common Stock

GRI Bio Strengthens Clinical Proof-of-Concept for GRI-0621 with Positive Phase 2a Study Data

GRI Bio announced additional positive data from a Phase 2a study in Idiopathic Pulmonary Fibrosis.

Regulatory and ClinicalJan 7, 2026 · 6:58pm ET

GRIGRI Bio, Inc. Common Stock+33.3%

GRI Bio Strengthens Clinical Proof-of-Concept for GRI-0621 with Positive Phase 2a Study Data

Regulatory and ClinicalJan 7, 2026 · 6:58pm ET

ACRVAcrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics Announced Positive Clinical Data for ACR-368 and ACR-2316, Nominated ACR-6840 as Next Development Candidate

Company revealed results from Phase 2b trial and initial clinical data.

Regulatory and ClinicalJan 7, 2026 · 6:58pm ET

ACRVAcrivon Therapeutics, Inc. Common Stock+38.7%

Acrivon Therapeutics Announced Positive Clinical Data for ACR-368 and ACR-2316, Nominated ACR-6840 as Next Development Candidate

Regulatory and ClinicalJan 5, 2026 · 6:59pm ET

ALMSALUMIS INC.

Alumis Inc. Announces Positive Topline Results for Phase 3 Trials of Envudeucitinib

Envudeucitinib shows significant efficacy in treating moderate-to-severe plaque psoriasis.

Regulatory and ClinicalJan 5, 2026 · 6:59pm ET

ALMSALUMIS INC.+168.9%

Alumis Inc. Announces Positive Topline Results for Phase 3 Trials of Envudeucitinib

Regulatory and ClinicalJan 5, 2026 · 3:59pm ET

RNAZTranscode Therapeutics, Inc.

TransCode Therapeutics Announces Publication of Preclinical Data for TTX-MC138 in Glioblastoma

The data supports the therapeutic potential of TTX-MC138.

Regulatory and ClinicalJan 5, 2026 · 3:59pm ET

RNAZTranscode Therapeutics, Inc.+47.0%

TransCode Therapeutics Announces Publication of Preclinical Data for TTX-MC138 in Glioblastoma

Regulatory and ClinicalDec 16, 2025 · 7:49pm ET

PCSAProcessa Pharmaceuticals, Inc.

Processa Pharmaceuticals Updated Phase 2 Study of NGC-Cap in Breast Cancer Patients

Company provided a clinical update on December 17, 2025.

Regulatory and ClinicalDec 16, 2025 · 7:49pm ET

PCSAProcessa Pharmaceuticals, Inc.+204.0%

Processa Pharmaceuticals Updated Phase 2 Study of NGC-Cap in Breast Cancer Patients

1
…
8
9
10
…
24

RVOL

1.0x

Max high

$46.77

Fuel

4h 27m

RVOL

8.4x

Max high

$11.03

Fuel

15m

RVOL

4.1x

Max high

$4.09

Fuel

2h 36m

RVOL

10.6x

Max high

$22.35

Fuel

4h 9m

RVOL

6.9x

Max high

$10.35

Fuel

8m

RVOL

10.9x

Max high

$9.88

Fuel

2m